Rare Cancers Bill

Monica Harding Excerpts

Friday 11th July 2025 Commons Chamber

[Monica Harding (Esher and Walton) (LD)]

I once more thank the hon. Member for Edinburgh South West (Dr Arthur) for all he has done to bring the Bill forward. We, along with thousands of families throughout the UK, all owe him a huge debt. I am proud to have supported the Bill from the very beginning. I also pay tribute to the ongoing work of the hon. Member for Mitcham and Morden (Dame Siobhain McDonagh), whose inspirational advocacy has set the example on these issues, particularly for new MPs like me.

I do not think I need take up much time restating why the Rare Cancers Bill matters; every hon. Member who sat alongside me in the Bill Committee knows that already, which is why we reported it to the House unamended. The Minister also knows, which is why the Government have repeatedly pledged their support, and organisations working with rare cancers know too. The Brain Tumour Charity describes this legislation as “a Bill of hope” and Pancreatic Cancer UK talks of its potential to transform survival for rare cancers. That potential sits with us today.

The Rare Cancers Bill takes concrete and common-sense steps to facilitate research into rare cancers, to improve the speed and quality of necessary clinical trials, and to help get orphan drugs—medicines often neglected because they target uncommon conditions—to those patients who so desperately need them. I urge the House to advance the Bill and ensure that its provisions become law as rapidly as possible. So much depends on getting this one right. To that end, I briefly remind the House what exactly is at stake today for families, including my own, throughout this country.

When I spoke on Second Reading, I told the story of Group Captain Pip Harding, my brother-in-law, who was diagnosed with an aggressive stage 4 glioblastoma in February 2024. His prognosis was such that he should not be here today. Pip is married with five children. He has served in the Royal Air Force in the Indo-Pacific, in Afghanistan and in Iraq. I am immensely proud of him, not least because of his battle against this devastating diagnosis.

Pip’s family, friends and those who loved him rallied around him. More than 600 of them set up a GoFundMe page to cover the cost of an experimental cancer treatment, oncothermia, which uses radio frequencies to target and treat malignant cancer cells. I am happier than I can say to be able to tell the House that Pip is alive and well, and that the tumour has shrunk from 7cm to less than 1 cm as a result of that treatment. For Pip’s loved ones, of course, that means the world—oncothermia is winning it for him. It means that there is more time for his family and more time for more treatments to come online to get his health back.

[Dame Siobhain McDonagh (Mitcham and Morden) (Lab)]

It is a matter of delight that the hon. Lady’s brother-in-law is still well and that the tumour has shrunk. But I should say to the House and all Members that that machine, which my late sister campaigned and raised funding for, is currently situated in a private hospital in London because it would get nowhere near an NHS hospital. That is the tragedy of the circumstances that we find ourselves in: our system is so restrictive that we cannot look for new innovations within our NHS.

--- Later in debate ---

[Monica Harding]

I thank the hon. Member for all her advocacy on the issue. She makes an important point, which was made previously: rare cancers are not rare for the victims and their families. That is why we need to bring such treatments into the NHS so that they are available for all, not just for those who set up GoFundMe pages that win tens of thousands of pounds.

Of glioblastoma, Pip said:

“This is a very sad disease of which the cause is…unknown and seems to randomly strike individuals. It would be just amazing if the policy to support these people was changed by this vote and I am personally so grateful to all of you who are so kindly driving this forward.”

His successful story and the challenge of accessing oncothermia underscore equally the importance of the legislation. In sum, innovative new treatments for rare cancers must be brought to patients as fast as possible.

My constituents in Esher and Walton, particularly those whose lives have been scarred by cancer, also feel that very deeply. In the last few days, many have written to me about the legislation to share why its success matters so much to them. One told me of his very young son, who was diagnosed last year with a rare brain tumour that has turned their lives upside down. One told me about his own battle with brain cancer, the excellent care that he has received in the NHS and the fundamentally limited treatment options available to him based on the current state of research and drug development and marketing. Another constituent whose daughter has glioblastoma offered me an important reminder about our work today when they said that

“every important issue or gain has to be fought over fiercely before anything is achieved.”

They are absolutely right.

I will take this opportunity to highlight some other people who have fought and for whom the Bill is vital. My constituent Kate Ford has been campaigning for the lobular moonshot project since she was diagnosed with lobular breast cancer two years. We have already heard how research for that disease has been entirely insufficient and how necessary that project is right now. I am proud to be one of hundreds of MPs on both sides of the House calling on the Government to support it, as we have heard. Like the hon. Members for Farnham and Bordon (Gregory Stafford) and for Bishop Auckland (Sam Rushworth), I was deeply saddened to hear of the death of Dr Susan Michaelis, the project’s founder, this week. My constituent Kate is now carrying forward Susan’s torch and will be at the meeting with the Secretary of State for Health and Social Care on Monday. I call on the Government to answer Susan’s call and finally back the project.

While I have the Government’s attention, I will raise one more important issue. Pip was an RAF helicopter pilot. There are a growing number of veterans who served as aircrew on military helicopters and were exposed to exhaust fumes during their time in the forces, and who have now been diagnosed with rare cancers, including blood cancers. That issue has been raised in recent months by hon. Members on both sides of the House, including my hon. Friend the Member for North Shropshire (Helen Morgan) and the hon. Member for Truro and Falmouth (Jayne Kirkham).

I understand that the Ministry of Defence is currently working to test engine exhaust emissions and to develop a clearer understanding of the health challenges facing veterans, including rare cancers related to their service. Those are welcome steps, but they are insufficient. Although I am conscious that the MOD does not unequivocally recognise the link between exhaust fumes and such cancers, and that I am not addressing the Minister for Veterans, I urge the Minister to do all he can to accelerate the collation of veterans’ health data, which is an essential project that could otherwise drag on, and to support the development of cancer screening programmes for veterans who may be at risk due to their record of serving this country.

Cancer can touch any life. It can come unexpectedly, and it can come cruelly. The Bill offers hope to all those whose cancer has been neglected and disregarded in drug research and clinical trials, but has upended their entire life. It offers us the chance to say to all those people, “You are not alone and you are not forgotten.”

Winning the battle against rare cancers requires us to advance on many fronts at once, so I gently push the Minister, even as he supports the Bill becoming law, to consider the vital calls from the hon. Member for Mitcham and Morden to improve outcomes for brain cancer patients, which have shown too little improvement for too long. Will the Minister commit to a target of getting 200 glioblastoma patients on to promising new clinical trials every year? Will he engage with the private sector to urge pharmaceutical companies to more rapidly make their drugs available for those trials? Will he consider mandating training in brain cancer specific oncology for all doctors seeking to become medical oncologists? Will he also ensure that all neuro-oncology multidisciplinary teams have as a core member a medical oncologist able to contribute their expertise to a patient’s care?

Finally, even as we advance the Bill today, we must not lose sight of the need to do far better by patients with cancer, rare or not. One of the most reassuring aspects of this Bill has been its cross-party support, but while I am here, I want to ask the Minister whether he will listen to Liberal Democrat calls and turn the current target of starting treatment within 62 days of an urgent cancer referral into an iron-clad guarantee? Will he also consider our call to expand the capacity of the Medicines and Healthcare products Regulatory Agency as another way of ensuring that innovative drugs are not snarled up in red tape and that they reach patients faster?

There is much work left to do, but today’s legislation is a real step in the right direction. I take note of the humbleness of the hon. Member for Edinburgh South West, so I will speak about the reach of the Bill and his work. Good politics changes lives and the best politics saves lives. All of us here in this place are committed to do that. I am proud to support this Bill, and I urge Members to vote for all those lives that the Bill could help save and for those families whose lives it will change.